glp-1 kaiser 📌 Starting January 1, 2025, Permanente will be making adjustments to the coverage of drugs and other Anti-Obesity Medications (AOMs) in California commercial plans. For members with a BMI less What you need to know

Routine Laboratory Monitoring: While semaglutide doesn't require specific blood test monitoring beyond standard diabetes care, informing your primary care physician ensures appropriate interpretation of glucose, HbA1c, and other metabolic parameters

Blood and urine tests are used to assess and monitor kidney function and diagnose CKD

Key highlights: Once-daily oral administration No food or water restrictions No injections required ~12% mean weight loss in Phase 3 trials Improvements in cardiometabolic risk markers Indication: Approved for adults with obesity, or overweight individuals with weight-related comorbidities, alongside reduced-calorie diet and increased physical activity

I dont think of this as a performance-enhancing drug in the same way as EPO or an anabolic steroid, McGuire says

Let our values Patients, Science, Passion drive our decisions to success

This was 1.5-fold higher than the rate in 2023, which was 9.9 prescriptions per 100,000 adolescents